MediBeacon, Inc. appears in FDA device records as the applicant for a single premarket approval, P230019, covering a transdermal test for assessment of glomerular filtration rate. The original approval was decided on January 17, 2025, and a later supplement, P230019/S005, was decided on October 2, 2026. The supplied filings describe a system built around an injectable fluorescent tracer and a monitor that calculates and displays a transdermal GFR value. The record set is narrow: two linked PMA records, both approvals, with no recall entries in the supplied sample. [1][2][5][8]
The approved device and its components
The FDA approval letter identifies the trade name as the MediBeacon® Transdermal GFR Measurement System (TGFR), product code SDK, filed June 21, 2023, with amendments through August 2024 and a decision dated January 17, 2025. The summary of safety and effectiveness data gives the generic name as Transdermal GFR System and lists the applicant as MediBeacon Inc. at 425 N New Ballas Road, Suite 100, St. Louis, MO 63141, an FDA filing address. A clinician brochure published by MediBeacon describes the TGFR as comprising Lumitrace® injection, a fluorescent tracer agent; a TGFR Sensor with light source and photo detector; and a TGFR Monitor that calculates and displays transdermal GFR. [5][7][8]
The approved indication, as stated in the PMA record, is assessment of glomerular filtration rate in adult patients with impaired or normal renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent over time, with validation in patients with stable renal function. Lumitrace® is described as an injectable exogenous fluorescent tracer indicated for use with TGFR for GFR assessment. The same record lists exclusions from approval; those clinical boundaries are left to the labeling. [2]
Supplement S005 and manufacturing scope
P230019/S005 was received September 17, 2026 and decided October 2, 2026 as a Special (Immediate Track) supplement under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The approval statement covers an additional package integrity test method for routine testing of Lumitrace and additional verification steps in the monitor manufacturing process. The advisory committee recorded for both the original PMA and the supplement is Gastroenterology, Urology. [1][2]
The summary of safety and effectiveness data states that the applicant's manufacturing facilities were inspected and found in compliance with the device Quality System regulation at 21 CFR 820. That statement belongs to the original PMA review; the supplement record documents the process change without describing inspection outcomes of its own. [1][5]
What the filing record shows, and what it does not
The supplied collection contains two linked PMA records, both with an approval decision, and the smaller record sample contains the same two entries: P230019 decided January 17, 2025 and P230019/S005 decided October 2, 2026. These counts describe the supplied filings as of the snapshot date and are not a measure of total company portfolio, sales or safety performance. No recall records appear in the supplied sample. [1][2]
Several details are not established by these sources. Corporate ownership, parent or brand relationships, headquarters separate from the FDA filing address, website operations, customer relationships, commercial availability and post-market performance are not documented here and remain unknown. The FDA PMA page notes that a device with supplements may have a changed description or indication and directs readers to the supplements and labeling for current information. [3][5]
